一、限制性股票的预留授予情况 1、 预留授予日：2025 年 9 月 29 日； 证券代码：002821 证券简称：凯莱英 公告编号：2025-065 凯莱英医药集团（天津）股份有限公司 关于 A 股限制性股票预留授予登记完成的公告 本公司及全体董事会成员保证公告内容真实、准确和完整，不存在虚 假记载、误导性陈述或重大遗漏。 重要内容提示 2025 年 1 月 24 日，公司第四届董事会第五十九次会议审议通过《关于公司〈2025 年 A 股限制性股票激励计划（草案）〉及其摘要的议案》。2025 年 3 月 18 日，公司第 四届董事会第六十次会议审议通过《关于公司〈2025 年 A 股限制性股票激励计划（草 案）〉及其摘要修订稿的议案》。2025 年 4 月 3 日，公司 2025 年第一次临时股东大会 审议并通过了《关于公司〈2025 年 A 股限制性股票激励计划（草案）〉及其摘要修订 稿的议案》。2025 年 9 月 29 日，公司第五届董事会第四次会议审议通过了《关于向激 励对象授予预留 A 股限制性股票的议案》。根据中国证监会《上市公司股权激励管理 办法》、深圳证券交易所、中国证券登记结算有限责任公司 ...

智通财经APP讯，凯莱英(06821)发布公告，于2025年11月27日授出29.14万股A股限制性股票。 ...

Core Viewpoint - 凯莱英 announced the grant of 291,400 restricted A-shares on November 27, 2025 [1] Summary by Category - **Company Actions** - The company will issue 291,400 restricted A-shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 公司名稱： 凱萊英醫藥集團（天津）股份有限公司 呈交日期： 2025年11月27日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | A股（深圳證券交易所） | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 事件 | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | | 已發行股份（不包括庫存股份）數 | 佔有關事件前的現有已發 行股份（不包括庫存股 | 庫存股 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第13.10B條作出。 茲載列本公司在深圳證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 凱萊英醫藥集團（天津）股份有限公司 凯莱英医药集团（天津）股份有限公司 关于 A 股限制性股票预留授予登记完成的公告 本公司及全体董事会成员保证公告内容真实、准确和完整，不存在虚 假记载、误导性陈述或重大遗漏。 Hao Hong博士 董事長、執行董事兼首席執行官 中國天津，二零二五年十一月二十七日 於本公告日期，本公司董事會由董事長兼執行董事 Hao Hong 博士，執行董事楊蕊女士 、張達先生及洪亮先生，非執行董事 Ye Song 博士及張 ...

Core Viewpoint - The overseas CXO industry has shown resilience under macroeconomic pressure, with overall sentiment stabilizing after hitting a bottom, suggesting a recovery in the domestic CXO sector as macro indicators like interest rates and financing improve [1] Group 1: Industry Overview - The overseas CXO industry has confirmed its bottom and is showing a structural recovery trend, with significant differentiation in recovery across sectors [2] - Clinical CROs, represented by companies like IQVIA and Medpace, are leading the recovery due to strong orders and forward guidance [2] - CDMOs, exemplified by Lonza, demonstrate resilience through long-term contracts, while preclinical CROs and research services are still in a bottoming phase [2] Group 2: Clinical CRO Insights - IQVIA shows positive data with a net book-to-bill ratio of 1.15 and a 20% year-on-year increase in RFP flow, with cancellations returning to a normalized $2.2 billion from over $3 billion [3] - Medpace exhibits the strongest performance with a net book-to-bill ratio of 1.20 and a pre-backlog exceeding $3 billion, indicating high revenue visibility for 2026 [3] - ICON is experiencing demand recovery, but short-term performance is affected by project execution volatility, with a net book-to-bill ratio of 1.02 due to $900 million in project cancellations [3] Group 3: CDMO Insights - Lonza maintains stable performance with strategic long-term contracts and a structure that provides immunity to biotech financing fluctuations [4] - Samsung Biologics keeps its revenue growth guidance unchanged at approximately 25%-30%, with total contract amounts exceeding $20 billion, showcasing strong order reserves [4] - Syngene faces short-term profitability pressure but is entering a critical phase of capacity upgrades and order increases with new global clinical orders [4] Group 4: Investment Recommendations - Companies with global competitive advantages in the CXO sector include WuXi AppTec, WuXi Biologics, and others [4] - Focus on innovative drug industry chain companies with improving profitability, such as Haoyuan Pharmaceutical [4] - Attention is also recommended for companies primarily generating domestic revenue, expected to recover as innovative drugs expand internationally, like Tigermed [4]

Core Viewpoint - Despite a slowdown in the sector in the second half of the year, there remains strong interest from capital, with nearly 8 billion yuan of net inflow over five consecutive trading days, indicating a new round of investment layout [1] Group 1: Global Trends - Over the past decade, the number of pharmaceutical transactions globally has shown a steady growth trend, with multinational corporations (MNCs) needing to replenish their pipelines due to profit pressures [1] - By 2030, products with sales exceeding 5 billion USD that are nearing patent expiration will total nearly 200 billion USD, driving MNCs' enthusiasm for business development (BD) [1] Group 2: Chinese Pharmaceutical Companies - Chinese pharmaceutical companies are increasingly competitive globally, with the total amount of license-out transactions exceeding 100 billion USD this year, doubling compared to 2024 [2] - From 2015 to 2024, the number of original innovative drugs entering clinical trials from Chinese companies reached 4,382, surpassing the 4,009 from the United States, with 704 new drugs entering clinical trials in 2024, ranking first globally [2] - The number of innovative drugs developed by Chinese companies that have entered late-stage clinical trials is comparable to that of the United States [2] Group 3: Technological Trends - Antibody-drug conjugates (ADC) have become a hot topic for license-out transactions among Chinese companies over the past three years, transitioning from a follower to a leader in innovation [2] - Chinese companies are rapidly following innovations in immuno-oncology (IO) and have the potential to surpass competitors, with some products already authorized for international markets [2] Group 4: Policy Environment - The average price reduction of drugs in the 2025 medical insurance negotiations is expected to stabilize, with a significant proportion of newly added drugs being domestically produced [3] - Future centralized procurement may focus more on comprehensive value assessments rather than solely on low prices, emphasizing efficacy, quality, and patient accessibility [3] Group 5: Investment Opportunities - Focus on IO and ADC as foundational therapies for tumors, particularly with the upcoming expiration of PD-1 patents, which may lead to a market shift towards second-generation IO therapies [3] - Highlighted companies in the IO and ADC sectors include: 3SBio, Innovent Biologics, CanSino Biologics, Rongchang Biopharmaceuticals, Huahai Pharmaceutical, Yiming Pharmaceutical, Lepu Medical, Kelun-Biotech, and CSPC Pharmaceutical [3][5] - Emphasis on the internationalization of Chinese pharmaceutical companies, with a long-term view of the industry evolving into global leaders, particularly in innovative drugs and medical devices [3] - Notable companies in the medical device sector include Mindray Medical, United Imaging Healthcare, BGI Genomics, and Haitai New Light [3][5] - The CXO industry is expected to improve due to better supply-demand dynamics, with global investment recovery likely to boost client demand [4] - Key CXO leaders to watch include WuXi AppTec, WuXi Biologics, Kelun Pharmaceutical, Tigermed, and Jiuzhou Pharmaceutical [4][5]

Core Insights - The medical services sector experienced a slight increase of 0.45% on November 26, with Lanwei Medical leading the gains [1] - The Shanghai Composite Index closed at 3864.18, down 0.15%, while the Shenzhen Component Index closed at 12907.83, up 1.02% [1] Medical Services Sector Performance - Lanwei Medical (301060) closed at 10.79, up 7.90%, with a trading volume of 410,000 shares and a transaction value of 444 million yuan [1] - Sunshine Nuohuo (688621) closed at 68.55, up 7.63%, with a trading volume of 78,800 shares and a transaction value of 537 million yuan [1] - ST Zhongzhu (600568) closed at 2.70, up 5.06%, with a trading volume of 853,900 shares and a transaction value of 230 million yuan [1] - Chengdu Xian Dao (688222) closed at 23.40, up 2.45%, with a trading volume of 110,000 shares and a transaction value of 260 million yuan [1] - Other notable performers include Yaokang Bio (688046) and Kailai Ying (002821), with increases of 2.03% and 2.02% respectively [1] Capital Flow Analysis - The medical services sector saw a net inflow of 307 million yuan from institutional investors, while retail investors experienced a net outflow of 219 million yuan [2] - Major stocks like Yao Ming Kang De (603259) and Chengda Pharmaceutical (301201) had significant capital movements, with net inflows of 26.1 million yuan and 10.4 million yuan respectively [3] - Conversely, stocks like Bi De Pharmaceutical (688073) and Haochen Medical (002622) faced net outflows of 4.6% and 2.07% respectively [2][3]

Market Overview - The medical services sector increased by 0.56% on November 25, with ST Zhongzhu leading the gains [1] - The Shanghai Composite Index closed at 3870.02, up 0.87%, while the Shenzhen Component Index closed at 12777.31, up 1.53% [1] Top Gainers in Medical Services - ST Zhongzhu (600568) closed at 2.57, up 4.90% with a trading volume of 53,900 shares and a turnover of 13.85 million yuan [1] - Chengda Pharmaceutical (301201) closed at 47.78, up 2.97% with a trading volume of 112,700 shares and a turnover of 540 million yuan [1] - Boji Pharmaceutical (300404) closed at 10.10, up 2.75% with a trading volume of 108,600 shares and a turnover of 10.9 million yuan [1] Top Losers in Medical Services - Jiuzhou Pharmaceutical (603456) closed at 18.75, down 0.85% with a trading volume of 181,100 shares and a turnover of 343 million yuan [2] - Tongce Medical (600763) closed at 41.95, down 0.66% with a trading volume of 49,600 shares and a turnover of 210 million yuan [2] - Yingkang Life (300143) closed at 10.12, down 0.49% with a trading volume of 44,700 shares and a turnover of 4.56 million yuan [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 113 million yuan from institutional investors, while retail investors saw a net inflow of 30.37 million yuan [2][3] - Major stocks like WuXi AppTec (603259) had a net inflow of 67.13 million yuan from institutional investors, while Sunshine Nuohua (688621) saw a net outflow of 2.29 million yuan from retail investors [3] Summary of Individual Stock Performance - Sunshine Nuohua (688621) had a net inflow of 38.24 million yuan from institutional investors, but a net outflow of 3.59 million yuan from retail investors [3] - Chengda Pharmaceutical (301201) also saw a significant net inflow of 36.45 million yuan from institutional investors, with a net outflow of 13.58 million yuan from retail investors [3] - New Mileage (002219) had a net inflow of 14.15 million yuan from institutional investors, while retail investors experienced a net outflow of 6.70 million yuan [3]

Core Insights - The article highlights the net inflow and outflow of funds in the Hong Kong stock market, with specific focus on the top performers and laggards in terms of capital movement [1][2][3] Fund Inflows - The top three stocks with the highest net inflow are: - 盈富基金 (02800) with a net inflow of 74.33 billion, representing a 24.09% increase in capital [2] - 恒生中国企业 (02828) with a net inflow of 19.17 billion, showing a 29.84% increase [2] - 南方恒生科技 (03033) with a net inflow of 14.88 billion, reflecting a 14.32% increase [2] Fund Outflows - The top three stocks with the highest net outflow are: - 小米集团-W (01810) with a net outflow of -6.11 billion, indicating a -4.66% decrease [2] - 泡泡玛特 (09992) with a net outflow of -2.74 billion, showing an -8.07% decrease [2] - 兖矿能源 (01171) with a net outflow of -1.84 billion, reflecting a -43.34% decrease [2] Net Inflow Ratios - The stocks with the highest net inflow ratios are: - 南方港美科技 (03442) at 75.22% with a net inflow of 711.95 million [2] - 工银南方中国 (03167) at 75.00% with a net inflow of 10.4 million [2] - 保诚 (02378) at 64.37% with a net inflow of 539.33 million [2] Net Outflow Ratios - The stocks with the highest net outflow ratios are: - 中国春来 (01969) at -67.51% with a net outflow of -146.76 million [3] - 丘钛科技 (01478) at -58.59% with a net outflow of -969.83 million [3] - 中国东方教育 (00667) at -56.10% with a net outflow of -1830.56 million [3]